

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |  |  |
|---|--|--|
| <b>TRANSMITTAL LETTER TO THE UNITED STATES<br/>DESIGNATED/ELECTED OFFICE (DO/EO/US)<br/>CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>   |  | ATTORNEY'S DOCKET NUMBER<br><b>701039-55264</b>                      |
| INTERNATIONAL APPLICATION NO.<br><b>PCT/US2005/014210</b>   |  | U.S. APPLICATION NO. (If known, see 37 CFR 1.5)<br><b>10/535,746</b> |
| INTERNATIONAL FILING DATE<br><b>26 April 2005 (26.04.2005)</b>  |  | PRIORITY DATE CLAIMED<br><b>26 April 2004 (26.04.2004)</b>           |
| TITLE OF INVENTION <b>PLATELET BIOMARKERS FOR THE DETECTION OF DISEASE</b>  |  |  |
| APPLICANT(S) FOR DO/EO/US <b>CHILDREN'S MEDICAL CENTER CORPORATION; FOLKMAN, Judah and KLEMENT, Giannoula</b>   |  |  |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:   |  |  |
| <p>1. <input type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input checked="" type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is attached hereto.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A preliminary amendment.</p> <p>14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> |  |  |

Rec'd PCT/PTC 9 SEP 2005

PTO-1390 (Rev. 07-2005)  
Approved for use through 3/31/2007. OMB 0651-0021  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |              |   |         |   |              |
|---|--------------|---|---------|---|--------------|
| U.S. APPLICATION NO. (if known, see 37 CFR 1.5)<br><b>10/535,746</b>  |              | INTERNATIONAL APPLICATION NO.<br><b>PCT/US2005/014210</b>                     |         | ATTORNEY'S DOCKET NUMBER<br><b>701039-55264</b> |              |
| 20. Other items or information:<br><b>Exp. Mail Cert. EV653001429US; COPY-Limited Recognition; Letter to Examiner; Transmittal of Formal Drawings; Formal Drawings; and Return Receipt Postcard.</b>  |              |   |         |   |              |
| The following fees have been submitted  |              |   |         | CALCULATIONS                                    | PTO USE ONLY |
| 21. <input type="checkbox"/> Basic national fee (37 CFR 1.492(a))..... <b>\$300</b>   |              |   |         | \$  |              |
| 22. <input type="checkbox"/> Examination fee (37 CFR 1.492(c))  |              |   |         | \$  |              |
| If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... <b>\$0</b>  |              |   |         | \$  |              |
| All other situations..... <b>\$200</b>  |              |   |         |   |              |
| 23. <input type="checkbox"/> Search fee (37 CFR 1.492(b))   |              |   |         | \$  |              |
| If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... <b>\$0</b>   |              |   |         |   |              |
| Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... <b>\$100</b>   |              |   |         |   |              |
| International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... <b>\$400</b>  |              |   |         |   |              |
| All other situations..... <b>\$500</b>  |              |   |         |   |              |
| <b>TOTAL OF 21, 22 and 23 =</b>   |              |   |         | <b>0.00</b>                                     |              |
| <input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).<br>The fee is \$250 for each additional 50 sheets of paper or fraction thereof. |              |   |         |   |              |
| Total Sheets  | Extra Sheets | Number of each additional 50 or fraction thereof (round up to a whole number) | RATE    |   |              |
| - 100 =   | /50 =        |   | x \$250 | \$  | 0.00         |
| Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).   |              |   |         | \$  | 0.00         |
| CLAIMS  | NUMBER FILED | NUMBER EXTRA  | RATE    | \$  |              |
| Total claims  | - 20 =       |   | x \$ 50 | \$  |              |
| Independent claims  | - 3 =        |   | x \$200 | \$  |              |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable)   |              |   | + \$360 | \$  |              |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>  |              |   |         | <b>\$ 0.00</b>                                  |              |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.  |              |   |         |   |              |
| <b>SUBTOTAL =</b>   |              |   |         | <b>\$ 0.00</b>                                  |              |
| Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).   |              |   |         | \$  | 0.00         |
| <b>TOTAL NATIONAL FEE =</b>   |              |   |         | <b>\$ 0.00</b>                                  |              |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property  |              |   |         | \$  | 0.00         |
| <b>TOTAL FEES ENCLOSED =</b>  |              |   |         | <b>\$ 0.00</b>                                  |              |
|   |              |   |         | Amount to be refunded:                          | \$           |
|   |              |   |         | Amount to be charged                            | \$           |


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0850. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

David S. Resnick  
Nixon Peabody LLP  
100 Summer Street  
Boston, MA 02110  
US



SIGNATURE

David S. Resnick/Leena H. Karttunen  
NAME

34,235/L0207  
REGISTRATION NUMBER

**Rec'd PCT/PTO****SEP 2005**

Practitioner's Docket No. 701039-55264

**PATENT****IN THE UNITED STATES RECEIVING OFFICE**

|   |                                       |   |
|---|---------------------------------------|---|
| <b>PCT/US2005/014210</b>                    | <b>26 April 2005<br/>(26.04.2005)</b> | <b>26 April 2004<br/>(26.04.2005)</b>           |
| <b>International<br/>Application Number</b> | <b>International<br/>Filing Date</b>  | <b>International Earliest<br/>Priority Date</b> |

**TITLE OF INVENTION: PLATELET BIOMARKERS FOR THE DETECTION OF DISEASE****APPLICANT(S) FOR EO/DO:** Children's Medical Center Corporation  
**INVENTOR(S)/APPLICANT(S) FOR US:** FOLKMAN, Judah et al.  
**U.S.S.N. 10/535,746****MAIL STOP PCT**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450****EXPRESS MAIL CERTIFICATE****"Express Mail" label number EV 653001429 US**  
**Date of Deposit September 9, 2005**I hereby state that the following *attached* paper or fee

1. Express Mail Certificate EV 653001429 US (1 pg.);
2. COPY-Limited Recognition (1 pp.);
3. Form 1390 – page 3 in duplicate (4 pp.);
4. Letter to Examiner (2 pp.);
5. Executed Oath and Declaration (3 pp.);
6. Supplemental Application Datasheet (6 pp.);
7. Transmittal of Formal Drawings (1 pg.);
8. Formal Drawings (37 pp.); and
9. Return Receipt Postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, on the date indicated above and is addressed to the MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Catherine Kearns

  
Signature of person mailing paper or fee

Rec'd PCT/PTC 9 SEP 2005

Practitioner's Docket No. 701039-55264


PATENT

IN THE UNITED STATES RECEIVING OFFICE

|                                     |                               |   |
|-------------------------------------|-------------------------------|---|
| PCT/US2005/014210                   | 25 April 2005<br>(25.04.2005) | 26 April 2004<br>(26.04.2005)           |
| International<br>Application Number | International<br>Filing Date  | International Earliest<br>Priority Date |

**TITLE OF INVENTION:** PLATELET BIOMARKERS FOR THE DETECTION OF DISEASE

**APPLICANT(S) FOR EO/DO:** Children's Medical Center Corporation  
**INVENTOR(S)/APPLICANT(S) FOR US:** FOLKMAN, Judah et al.  
**U.S.S.N. 10/535,746**

|   |
|---|
| <p align="center"><b>CERTIFICATE OF MAILING</b></p> <p>I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EV 653001429 US in an envelope addressed to MAIL STOP PCT, Commissioner of Patents, Box 1450, Alexandria, VA 22313-1450.</p> <p>Date: September 9, 2005</p> <p align="right"><br/>Catherine Kearns</p> |
|---|

MAIL STOP PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**LETTER TO EXAMINER**

On May 20, 2005, Applicants filed the application under 35 U.S.C. 371 in the United States Designated/Elected Office for the above-referenced international application. Enclosed herewith please find:

1. Executed Declaration and Power of Attorney (3 pp.);
2. Supplemental Application Datasheet (6 pp.);
3. Transmittal of Formal Drawings (1 pg.); and
4. Formal Drawings (37 pp.).

Applicants note that the surcharge for furnishing the oath or declaration late was previously paid with the May 20, 2005 national entry. Accordingly, Applicants believe that no fee is due at this time.

Please charge any fees that may be due in connection with this matter to Deposit Account No. 50-0850.

## IN THE UNITED STATES RECEIVING OFFICE

|                                  |                               |                                      |
|----------------------------------|-------------------------------|--------------------------------------|
| PCT/US2005/014210                | 25 April 2005<br>(25.04.2005) | 26 April 2004<br>(26.04.2005)        |
| International Application Number | International Filing Date     | International Earliest Priority Date |

## TITLE OF INVENTION:

PLATELET BIOMARKERS FOR THE DETECTION OF DISEASE

APPLICANT(S) FOR EO/DO: Children's Medical Center Corporation

INVENTOR(S)/APPLICANT(S) FOR US: FOLKMAN, Judah et al.

U.S.S.N. 10/535,746

Please contact the undersigned if any additional information is needed.

Date: September 9, 2005

Respectfully submitted,



David S. Resnick (Reg. No. 34, 235)

Leena H. Karttunen (L0207)

NIXON PEABODY LLP

100 Summer Street

Boston, MA 02110

(617) 345-6057


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATES PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Leena H. Karttunen is hereby given limited recognition under 37 CFR § 11.9(b), as an employee of the law firm of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is a client of the law firm of Nixon Peabody LLP, and a registered practitioner, who is a member of the law firm of Nixon Peabody LLP, is the practitioner of record in the applications. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with the law firm of Nixon Peabody LLP, ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such limited recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. L0207  
Expires: September 30, 2005



Harry I. Moatz  
Director of Enrollment and Discipline